162 related articles for article (PubMed ID: 30194198)
21. Radiation safety considerations for the use of ²²³RaCl₂ DE in men with castration-resistant prostate cancer.
Dauer LT; Williamson MJ; Humm J; O'Donoghue J; Ghani R; Awadallah R; Carrasquillo J; Pandit-Taskar N; Aksnes AK; Biggin C; Reinton V; Morris M; St Germain J
Health Phys; 2014 Apr; 106(4):494-504. PubMed ID: 24562070
[TBL] [Abstract][Full Text] [Related]
22. Hematopoiesis is prognostic for toxicity and survival of
Leisser A; Nejabat M; Hartenbach M; Duan H; Shariat SF; Kramer G; Krainer M; Hacker M; Haug AR
Hell J Nucl Med; 2017; 20 Suppl():157. PubMed ID: 29324927
[TBL] [Abstract][Full Text] [Related]
23. Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.
Heidenreich A; Gillessen S; Heinrich D; Keizman D; O'Sullivan JM; Carles J; Wirth M; Miller K; Reeves J; Seger M; Nilsson S; Saad F
BMC Cancer; 2019 Jan; 19(1):12. PubMed ID: 30612558
[TBL] [Abstract][Full Text] [Related]
24. Radium Ra 223 dichloride in castration-resistant prostate cancer.
Joung JY; Ha YS; Kim IY
Drugs Today (Barc); 2013 Aug; 49(8):483-90. PubMed ID: 23977665
[TBL] [Abstract][Full Text] [Related]
25. Anaemia and thrombocytopenia in patients with prostate cancer and bone metastases.
Nieder C; Haukland E; Pawinski A; Dalhaug A
BMC Cancer; 2010 Jun; 10():284. PubMed ID: 20540802
[TBL] [Abstract][Full Text] [Related]
26. Haematopoietic toxicity of radium-223 in patients with high skeletal tumour burden.
Miederer M; Thomas C; Beck J; Hampel C; Krieger C; Baqué PE; Helisch A; Schreckenberger M
Nuklearmedizin; 2015; 54(5):197-203. PubMed ID: 26392087
[TBL] [Abstract][Full Text] [Related]
27. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.
Sartor O; Coleman R; Nilsson S; Heinrich D; Helle SI; O'Sullivan JM; Fosså SD; Chodacki A; Wiechno P; Logue J; Widmark A; Johannessen DC; Hoskin P; James ND; Solberg A; Syndikus I; Vogelzang NJ; O'Bryan-Tear CG; Shan M; Bruland ØS; Parker C
Lancet Oncol; 2014 Jun; 15(7):738-46. PubMed ID: 24836273
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and bone metastases in real-world practice: A multi-institutional study.
Matsumoto T; Hori Y; Shiota M; Blas L; Nakamura M; Seki N; Kuroiwa K; Yokomizo A; Morokuma F; Kiyoshima K; Eto M
Int J Urol; 2023 Feb; 30(2):139-146. PubMed ID: 36305673
[TBL] [Abstract][Full Text] [Related]
29. Changes in prostate-specific antigen, markers of bone metabolism and bone scans after treatment with radium-223.
Nome R; Hernes E; Bogsrud TV; Bjøro T; Fosså SD
Scand J Urol; 2015 Jun; 49(3):211-7. PubMed ID: 25515952
[TBL] [Abstract][Full Text] [Related]
30. Disease Characteristics and Completion of Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in an International Early Access Program.
Saad F; Gillessen S; Heinrich D; Keizman D; O'Sullivan JM; Nilsson S; Miller K; Wirth M; Reeves J; Seger M; Carles J; Heidenreich A
Clin Genitourin Cancer; 2019 Oct; 17(5):348-355.e5. PubMed ID: 31311763
[TBL] [Abstract][Full Text] [Related]
31. A prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population.
Badrising SK; Louhanepessy RD; van der Noort V; Coenen JLLM; Hamberg P; Beeker A; Wagenaar N; Lam MGEH; Celik F; Loosveld OJL; Oostdijk A; Zuetenhorst H; Haanen JB; Vegt E; Zwart W; Bergman AM;
Int J Cancer; 2020 Aug; 147(4):1143-1151. PubMed ID: 31875956
[TBL] [Abstract][Full Text] [Related]
32. [Principles, modalities and indications of the administration of Radium in cancers, focus on metastatic prostate cancer: State of arts].
Bertolaso P; Leroy L; Gross-Goupil M; Aupee O; Ravaud A; Roubaud G; Cazeau AL; Le Moulec S
Bull Cancer; 2017 Sep; 104(9):762-770. PubMed ID: 28797482
[TBL] [Abstract][Full Text] [Related]
33. Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases.
Nilsson S; Franzén L; Parker C; Tyrrell C; Blom R; Tennvall J; Lennernäs B; Petersson U; Johannessen DC; Sokal M; Pigott K; O'Bryan-Tear CG; Thuresson M; Bolstad B; Bruland ØS
Clin Genitourin Cancer; 2013 Mar; 11(1):20-6. PubMed ID: 23021204
[TBL] [Abstract][Full Text] [Related]
34. Radium-223 in the Treatment of Metastatic Castrate-Resistant Prostate Cancer.
Peters N; Bambury RM; Power DG; McCarthy L; Lyons C; Kelly P; Jamaluddin MF
Ir Med J; 2022 Feb; 115(2):536. PubMed ID: 35416462
[TBL] [Abstract][Full Text] [Related]
35. Clinical indicators for predicting prognosis after radium-223 administration in castration-resistant prostate cancer with bone metastases.
Yamamoto Y; Okuda Y; Kanaki T; Tanaka R; Nagahara A; Nakai Y; Nakayama M; Kakimoto KI; Nishimura K
Int J Clin Oncol; 2021 Jan; 26(1):192-198. PubMed ID: 32875513
[TBL] [Abstract][Full Text] [Related]
36. Radium-223 vs EBRT for multiple painful bone metastases: the data favor radium-223.
Vogelzang NJ
Oncology (Williston Park); 2014 Apr; 28(4):296, 298. PubMed ID: 24839800
[No Abstract] [Full Text] [Related]
37. Radium-223 therapy for metastatic castration-resistant prostate cancer: survival benefit when used earlier in the treatment pathway.
Jarvis P; Ho A; Sundram F
Nucl Med Commun; 2021 Mar; 42(3):332-336. PubMed ID: 33252512
[TBL] [Abstract][Full Text] [Related]
38. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.
Saad F; Carles J; Gillessen S; Heidenreich A; Heinrich D; Gratt J; Lévy J; Miller K; Nilsson S; Petrenciuc O; Tucci M; Wirth M; Federhofer J; O'Sullivan JM;
Lancet Oncol; 2016 Sep; 17(9):1306-16. PubMed ID: 27473888
[TBL] [Abstract][Full Text] [Related]
39. Radium-223 treatment in castration resistant bone metastatic prostate cancer. Should be the primary tumor always treated?
Serretta V; Valerio MR; Costa R; Tripoli V; Murabito A; Princiotta A; Scalici Gesolfo C; Borsellino N; Verderame F; Gebbia V; Licari M; Sanfilippo C;
Urol Oncol; 2019 Dec; 37(12):964-969. PubMed ID: 31601517
[TBL] [Abstract][Full Text] [Related]
40. Optimal usage of radium-223 in metastatic castration-resistant prostate cancer.
Cha TL; Wu TT; Vogelzang NJ; Huang CY; Huang SP; Lin CC; Ou YC; Pang ST; Shen DH; Wu WJ; Chang WY
J Formos Med Assoc; 2017 Nov; 116(11):825-836. PubMed ID: 29046247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]